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Exercise versus usual care after non-reconstructive breast cancer 
surgery (UK PROSPER): multicentre randomised controlled trial 
and economic evaluation
Julie Bruce,1 Bruno Mazuquin,2 Alastair Canaway,1 Anower Hossain,3 Esther Williamson,4  
Pankaj Mistry,1 Ranjit Lall,1 Stavros Petrou,5 Sarah E Lamb,6 Sophie Rees,1 Emma Padfield,1 
Raghavan Vidya,7 Alastair M Thompson,8 on behalf of the Prevention of Shoulder Problems  
Trial (PROSPER) Study Group
ABSTRACT
OBJECTIVE
To evaluate whether a structured exercise programme 
improved functional and health related quality of life 
outcomes compared with usual care for women at 
high risk of upper limb disability after breast cancer 
surgery.
DESIGN
Multicentre, pragmatic, superiority, randomised 
controlled trial with economic evaluation.
SETTING
17 UK National Health Service cancer centres.
PARTICIPANTS
392 women undergoing breast cancer surgery, at risk 
of postoperative upper limb morbidity, randomised 
(1:1) to usual care with structured exercise (n=196) or 
usual care alone (n=196).
INTERVENTIONS
Usual care (information leaflets) only or usual care 
plus a physiotherapy led exercise programme, 
incorporating stretching, strengthening, physical 
activity, and behavioural change techniques to 
support adherence to exercise, introduced at 7-10 
days postoperatively, with two further appointments 
at one and three months.
MAIN OUTCOME MEASURES
Disability of Arm, Hand and Shoulder (DASH) 
questionnaire at 12 months, analysed by intention to 
treat. Secondary outcomes included DASH subscales, 
pain, complications, health related quality of life, 
and resource use, from a health and personal social 
services perspective.
RESULTS
Between 26 January 2016 and 31 July 2017, 951 
patients were screened and 392 (mean age 58.1 
years) were randomly allocated, with 382 (97%) 
eligible for intention to treat analysis. 181 (95%) of 
191 participants allocated to exercise attended at 
least one appointment. Upper limb function improved 
after exercise compared with usual care (mean DASH 
16.3 (SD 17.6) for exercise (n=132); 23.7 (22.9) 
usual care (n=138); adjusted mean difference 7.81, 
95% confidence interval 3.17 to 12.44; P=0.001). 
Secondary outcomes favoured exercise over usual 
care, with lower pain intensity at 12 months (adjusted 
mean difference on numerical rating scale −0.68, 
−1.23 to −0.12; P=0.02) and fewer arm disability 
symptoms at 12 months (adjusted mean difference 
on Functional Assessment of Cancer Therapy-Breast+4 
(FACT-B+4) −2.02, −3.11 to −0.93; P=0.001). 
No increase in complications, lymphoedema, or 
adverse events was noted in participants allocated 
to exercise. Exercise accrued lower costs per patient 
(on average −£387 (€457; $533) (95% confidence 
interval −£2491 to £1718; 2015 pricing) and was cost 
effective compared with usual care.
CONCLUSIONS
The PROSPER exercise programme was clinically 
effective and cost effective and reduced upper limb 
disability one year after breast cancer treatment in 





Breast cancer treatments can affect the lymphatic 
and musculoskeletal systems of the torso and upper 
limb. Adverse sequelae after surgery and radiotherapy 
targeting the axilla are common, and up to one third 
of women experience restricted range of motion 
in the shoulder, chronic pain, and lymphoedema, 
limiting quality of life and delaying recovery.1 2 In 
the UK, guidelines for non-reconstructive breast 
surgery advocate gradual reintroduction of upper 
limb mobility, and referral to physiotherapy is 
recommended if problems develop.3 However, the 
optimal timing, intensity, safety, and impact of 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Upper limb disability is common after breast cancer treatment targeting the 
axilla, with up to one third of women experiencing problems postoperatively
Systematic reviews highlight the paucity of high quality trials, and uncertainty 
remains about whether early postoperative exercise may benefit patients at high 
risk of disability
No UK studies have assessed the clinical effectiveness or cost effectiveness of 
preventive strategies for patients at high risk of developing upper limb related 
disability after breast cancer treatment
WHAT THIS STUDY ADDS
Early, structured exercise was safe, and women had better arm function and 
health related quality of life, with less pain and limb related disability over one 
year compared with usual care
The PROSPER exercise programme was clinically impactful and cost effective
This trial provides the best quality evidence to date in support of early exercise 
for women at high risk of shoulder problems after breast cancer treatment
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postoperative exercise are uncertain, particularly 
in women undergoing axillary clearance surgery or 
axillary/supraclavicular radiotherapy, who are at 
increased risk of developing shoulder and upper limb 
related disability. Concerns include that early or overly 
vigorous exercise may increase risks of postoperative 
wound complications and lymphoedema.4 5 Systematic 
reviews highlight the paucity of evidence for the 
introduction of postoperative range of motion and 
strengthening exercises on functional outcomes.4  6  7 
Many published studies excluded higher risk groups, 
the very population that may benefit most from 
targeted support to prevent postoperative upper 
limb disability. No rigorous randomised controlled 
trials of sufficient sample size have been conducted 
to show the safety or clinical effectiveness of early 
exercise after breast cancer surgery among patients at 
the highest risk of developing upper limb disability. 
Few trials have examined function, health related 
quality of life, and other patient reported outcomes 
over the longer term. A systematic review found that 
evidence on the cost effectiveness of exercise and 
physiotherapy interventions for breast cancer patients 
was sparse.8 Before this study, no published (or 
registered) multicentre trial had evaluated whether 
early, structured, progressive postoperative exercise 
is clinically effective and cost effective for patients 
at higher risk of shoulder problems after targeted 
treatment to the axilla, supraclavicular area, or both 
(surgery/radiotherapy).
The aim of the UK Prevention of Shoulder Problems 
Trial (PROSPER) was to investigate the effects of an 
exercise programme compared with best practice usual 
care for women at high risk of upper limb disability 
after treatment for breast cancer. Outcomes included 
upper limb function, complications (pain, wound 
related complications, lymphoedema), health related 
quality of life, and cost effectiveness.
Methods
Study design
The UK PROSPER trial was a pragmatic, superiority, 
multicentre, randomised controlled trial undertaken at 
17 National Health Service (NHS) cancer centres. The 
trial protocol (version 2.1, 2017), a detailed description 
of the development of the intervention, and an 
embedded qualitative study have been published.9-11 
A protocol amendment was approved in 2018 to allow 
qualitative interviews with physiotherapists delivering 
the exercise intervention.
Participants
Women aged 18 years or older with newly diagnosed, 
histologically confirmed invasive or non-invasive breast 
cancer who were scheduled for surgery and considered 
to be at high risk of upper limb disability after surgery 
were eligible. We defined women as being at high risk if 
they were scheduled to undergo planned axillary node 
clearance or to have planned radiotherapy to the axilla 
or supraclavicular fossa, had a high body mass index 
(≥30), had existing shoulder problems as per PROSPER 
criteria (supplementary box S1), had any subsequent 
axillary surgery after sentinel lymph node biopsy, or 
had planned axillary or supraclavicular radiotherapy 
within six weeks of primary surgery. Patients informed 
of the need for axilla/supraclavicular radiotherapy 
were permitted postoperative entry to the trial only if 
the exercise intervention could be started within six 
weeks of the primary surgery.
Randomisation and masking
We randomly allocated participants (1:1) to usual 
care only or usual care plus structured exercise, 
using a computer generated sequence to ensure 
allocation concealment, via a secure, centralised 
telephone randomisation service administered by 
an independent programmer. The sequence was 
prepared by programmers and tested by the trial 
statistician. We used three stratification variables: 
recruitment centre, first or repeat surgery, and whether 
the patient was informed of the need for radiotherapy 
within six weeks of surgery. The nature of the exercise 
intervention meant that we did not blind participants 
or physiotherapists. Senior research team members 
were blind to treatment allocation for the duration of 
the trial. A statistician independent of the core trial 
team did the final statistical analyses.
Interventions
Participants randomised to best practice usual care 
were provided with written information leaflets 
recommending postoperative exercises and generic 
postoperative advice freely available from the UK 
charity Breast Cancer Care.12 13 Women allocated to 
usual care received no further intervention other than 
these leaflets, which were provided during preoperative 
clinics. Women randomised to the exercise programme 
also received these leaflets and were then referred to 
physiotherapy for a supervised, structured exercise 
programme. The programme was based on accepted 
principles of exercise prescription and progression; it 
was underpinned by behavioural change strategies, 
including motivational interview techniques, to 
encourage participants to adhere to exercise. The aim 
of the intervention was to restore range of movement in 
the shoulder, improve strength, and increase physical 
activity. We developed the intervention from literature 
review and consultation with stakeholders, including 
breast cancer patients undergoing active treatment, 
community cancer support groups, physiotherapists, 
rehabilitation specialists, and surgeons. The research 
team developed a draft intervention and refined it at an 
intervention development meeting with stakeholders. 
We produced a menu of upper limb exercises 
targeting shoulder flexion, abduction, and abduction 
with external rotation, from which the treating 
physiotherapist could prescribe an individually 
tailored programme.9 We produced materials to support 
adherence to exercise and integration of behaviour 
change techniques (for example, exercise booklet and 
exercise diary). We piloted the exercise programme 
with patients with newly diagnosed breast cancer.
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The final exercise programme was fully manualised 
with documented pathways for clinical assessment and 
exercise prescription, with guidance for management 
of postoperative complications. It consisted of at least 
three face-to-face therapy sessions with a trained 
physiotherapist (seven to 10 days, one month, and 
three months postoperatively), with participants 
permitted a maximum of six sessions over one year. 
The additional sessions could be delivered in person 
or by telephone.
The first session at seven to 10 days postoperatively 
was a one hour assessment by the physiotherapist. An 
individually tailored daily range of movement exercises 
was prescribed targeting shoulder flexion, abduction, 
and abduction with external rotation. Behavioural 
support strategies were used (collaborative goal 
setting, assessing confidence to exercise, exercise 
diary, identifying barriers, and facilitators to exercise). 
These were reviewed at subsequent sessions.
Follow-up sessions were of 30 minutes duration. 
From one month postoperatively, shoulder strength was 
assessed and strengthening exercises were prescribed 
to target deficits in shoulder flexion, abduction, and 
external rotation strength. Participants were given 
resistance bands (Therabands) for home use; these were 
used to tailor the level of resistance for each participant. 
Strength exercises were carried out at least twice a 
week. Participants were asked to gradually increase 
their physical activity with the aim of undertaking 150 
minutes of moderate intensity activity per week, in line 
with American Cancer Society guidance.14 At review 
sessions, the programme was progressed by increasing 
sets, repetitions, and resistance load of exercises and by 
progressing duration and intensity of physical activity. 
A detailed description of the exercise programme has 
been published separately.10
Procedures
After preoperative screening by oncology teams to 
identify women at higher risk of developing shoulder 
problems, eligible patients were provided with 
written trial information. Invitation packs included 
a baseline questionnaire, consent form, and usual 
care information leaflets. A trained member of the 
research team obtained informed consent. Participants 
randomly allocated to exercise were referred for the 
first physiotherapy assessment within seven to 10 
days of surgery. In this pragmatic trial, any other 
rehabilitation input beyond usual care was left to the 
discretion of the oncology team, as per normal clinical 
practice, and captured in questionnaires. We collected 
primary and secondary patient reported outcomes and 
resource use by using postal questionnaires at baseline 
(pre-randomisation) and six weeks, six months, and 12 
months post-randomisation. Follow-up questionnaires 
were mailed from and returned to the Warwick Clinical 
Trials Unit, independently of oncology teams. All 
baseline measures were ascertained preoperatively, 
except for late entry participants identified as being 
at high risk recruited within six weeks of surgery 
(recorded pre-randomisation).
Exercise intervention training and fidelity
Trial research staff trained 44 physiotherapists, 
with at least two physiotherapists trained from each 
participating NHS hospital. Physiotherapists were 
trained in trial procedures and the content and delivery 
of the exercise programme, including behavioural 
support strategies and motivational interviewing 
techniques. For each participant randomised to the 
exercise programme, physiotherapists completed 
treatment logs to record appointments, strength 
assessments, prescribed exercises, and overall progress 
with the programme. Research physiotherapists 
undertook intervention quality assurance checks 
by observing at least one therapy session with each 
physiotherapist, with consent from the trial participant. 
Verbal and written feedback on adherence to the study 
protocol was provided to all physiotherapists carrying 
out the exercise intervention.
Outcomes
The primary outcome was upper limb function 
assessed using the Disabilities of the Arm, Shoulder 
and Hand (DASH) questionnaire at 12 months post-
randomisation.15 Breast cancer treatments targeting 
the axilla and shoulder can affect upper limb function 
generally, leading to difficulty with activities such as 
writing, dressing, opening and closing jars, and lifting 
shopping bags. DASH is 30 item patient reported scale 
that ranges from no disability (score 0) to most severe 
disability (100).15 It includes 21 items of function, six 
items for symptoms, and three items on social/role 
function. DASH is recommended for measurement 
of upper extremity disorders in breast cancer 
survivors.16 17
Secondary outcomes, captured in follow-up 
questionnaires over 12 months, were DASH subscales 
(activity limitations, impairment, and participation 
restriction)18; postoperative pain (acute, chronic, 
and neuropathic pain),9 measured using a numerical 
rating scale, douleur neuropathique19; the Functional 
Assessment of Cancer Therapy-Breast+4 (FACT-B+4) 
arm symptom subscale20; complications (wound 
related, including surgical site infection, seroma, 
and wound healing); lymphoedema (Lymphoedema 
and Breast Cancer Questionnaire)21; and health 
related quality of life (measured by SF-12 and EQ-
5D-5L).22  23 We collected health and personal social 
service resource use data through self-report within 
postal questionnaires and extracted hospital resource 
use data from NHS Digital hospital episode statistics. 
Research staff extracted surgical and treatment related 
data from medical records after 12 months’ follow-up 
and transferred them to the Warwick Clinical Trials 
Unit via secure NHS data transfer pathways.
Sample size
The minimum clinically important difference for adults 
with acute or chronic upper extremity orthopaedic 
or rheumatological conditions for the DASH 
questionnaire is five to 10 points, suggesting moderate 
improvement.24  25 In a breast cancer population, a 
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small Dutch trial found a mean group difference of 
seven points at six months after a three month exercise 
intervention.26 We selected a seven point difference in 
DASH scores at 12 months to account for the preventive 
approach rather than treatment of an established, 
chronic condition and to allow for the pragmatic trial 
design, whereby some participants in the control 
arm may be exposed, by serendipity, to other active 
interventions. At 80% power and 5% type 1 error 
rate on a two sided test, we needed to randomise 242 
participants. The sample was inflated for therapist 
effects, with an estimated nine participants per 
therapist, yielding an intracluster coefficient of 0.01 
and design effect of 1.05, giving 256 participants. We 
allowed 25% loss to account for loss to follow-up over 
one year, giving a sample size of 350 participants.
Statistical and health economic analysis
The primary statistical analysis was an intention to 
treat analysis that included all participants in their 
randomised groups. We used an ordinary linear 
regression model to compare the primary outcome of 
DASH score at 12 months between treatment groups. 
We did a complier average causal effect analysis for 
the primary outcome for randomised participants who 
were fully adherent to the exercise programme, defined 
a priori as having at least three physiotherapy contacts. 
We analysed change in DASH score from baseline to six 
and 12 months by treatment arm and plotted mean 
changes (with 95% confidence intervals) graphically. 
Models were adjusted for age, baseline DASH score, 
breast surgery, axillary surgery, radiotherapy, and 
chemotherapy. We used similar methods to analyse the 
SF-12 data, comparing scores between treatment arms. 
We used multiple imputation to examine the effect of 
missing DASH data. We calculated “strength and work 
capacity” to reflect dose of strengthening exercises 
prescribed, defined as the product of repetitions and 
sets prescribed at each session; these data will be 
reported in a separate publication.
Within trial economic evaluation estimated the cost 
effectiveness of the exercise programme compared with 
usual care after breast cancer surgery (see economic 
evaluation in supplementary materials). The primary 
health economic analysis took the form of a cost-utility 
analysis, expressed in terms of incremental cost per 
quality adjusted life year (QALY) gained and incremental 
net monetary benefit. We captured intervention costs 
by using case report forms, and physiotherapists and 
the trial team collected intervention delivery data. 
We measured broader resource use with an adapted 
client service receipt inventory at six and 12 months’ 
follow-up. We calculated costs by combining resource 
use data with unit costs from standard sources 
such as the Personal Social Services Research Unit 
cost compendia.27 The primary measure of health 
consequence in the economic evaluation was the 
QALY. We used the Van Hout algorithm to derive utility 
values from the EQ-5D-5L, measured at baseline, six 
months, and 12 months.23 We estimated QALYs by 
using linear interpolation between utility values with 
the trapezoid rule. Additionally, for a subsample of 242 
participants (those with 12 months of complete data 
post-randomisation before the NHS Digital data cut-off 
date of 31 March 2018), we sourced secondary care 
use data on inpatient hospital spells and outpatient 
attendances over the duration of the trial from hospital 
episode statistics for financial years 2015-18 for 
sensitivity analyses.
The health economic analysis used the intention to 
treat principle. In line with guidance from the National 
Institute for Health and Care Excellence (NICE),28 the 
analysis adopted an NHS and Personal Social Services 
perspective. The price year for the analysis was 2015, 
which was when the trial intervention materials were 
developed. The health economic analysis used a 12 
month time horizon with no discounting of costs or 
outcomes. We used multiple imputation to correct for 
missing data, assumed to be missing at random. To 
maximise the use of available data, we used imputation 
at the component level (for example, for each healthcare 
cost variable and EQ-5D-5L assessment at each 
time point). We imputed costs and EQ-5D-5L utility 
scores jointly using chained equations and predictive 
mean matching; the imputation model included age, 
ethnicity, marital status, employment status, and 
recruiting site as covariates. We used hierarchical 
linear models to analyse the single cost and QALY 
endpoints and a hierarchical net benefit regression 
framework to jointly examine costs and consequences. 
We characterised uncertainty around cost effectiveness 
by using net benefit plots and cost effectiveness 
acceptability curves, in addition to multiple sensitivity 
analyses (see supplementary materials). We estimated 
the probability of cost effectiveness of the exercise 
programme for NICE thresholds of £20 000 and 
£30 000 per QALY gained. We provide further details 
on the methods for the economic evaluation and 
sensitivity analyses in supplementary materials.
Study monitoring
Trial steering and data monitoring committees 
reviewed safety, quality, and masked data at six 
monthly intervals and approved the statistical analysis 
plan and protocol. We did no interim analyses, but the 
trial steering committee/data monitoring committee 
could halt the trial for safety or ethical concerns. 
We obtained appropriate permissions and paid any 
required fees for use of copyright protected materials.
Patient and public involvement
Patients were involved at multiple stages, providing 
input to the design, management, and conduct of 
the trial. Patients and members of the public, from 
community cancer support groups, co-produced 
and reviewed exercise intervention materials.10 We 
included a lay member on the trial steering committee.
Results
Between 26 January 2016 and 31 July 2017, of 951 
women screened, 392 (41%) were randomly allocated 
to exercise and usual care (n=196) or usual care alone 
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(n=196). Ten (3%) patients were randomised in error 
and excluded from analyses as no data were collected: 
eight exclusions were due to surgical exclusions 
(bilateral/immediate breast reconstruction surgery), 
and two women withdrew immediately at the point of 
randomisation (fig 1). The remaining 382 participants 
were allocated to either usual care (n=191; 50%) or 
the exercise programme (n=191; 50%). The mean 
age of recruited participants was 58.1 (SD 12.1; range 
28-88) years. Overall, most participants had axillary 
node clearance (327/382; 86%) and/or axillary/
supraclavicular radiotherapy (317/382; 83%), and 
most (277/382; 73%) were overweight or obese at 
recruitment. One fifth (83/392; 21%) had a history 
of shoulder problems at recruitment. Table 1 shows 
participants’ characteristics by treatment group. 
Baseline patient reported outcome data were available 
for 350/382 (92%) of those allocated to treatment 
(175 per treatment group); 8% did not return baseline 
questionnaires.
We obtained postal questionnaire data for 303/382 
(79%) participants at six weeks, for 278/382 (73%) 
at six months, and for 274/382 (72%) at 12 months. 
Of those with complete baseline data, this equated to 
303/350 (87%) at six weeks, 278/350 (79%) at six 
months, and 274/350 (78%) at 12 months. Uptake to 
the exercise programme was high, with 181/191 (95%) 
participants allocated to exercise engaging with the 
intervention by attending at least one physiotherapy 
appointment; 143/191 (75%) were fully adherent, 
attending three or more sessions. Physiotherapists had 
a total of 622 contacts (mean 3.7; median 3) with 181 
participants who attended the exercise programme; 
97% (603/622) of contacts were face to face, and the 
remainder were telephone reviews (19/622; 3%). From 
quality assurance checks, treatment was delivered 
according to the protocol; only one physiotherapist 
needed refresher training and support after training on 
the intervention. Strength exercises were prescribed 
from one month postoperatively. We observed an 
increase in mean dose of strength exercises for 
upper limb movement directions over time among 
participants adhering to exercise; these data will be 
reported separately.
At 12 months post-randomisation, the mean DASH 
score was 16.3 (SD 17.6) for the exercise group and 
23.7 (22.9) for the usual care group (table 2). The 
intention to treat analysis showed a statistically and 
Women with invasive or non-invasive cancer
Ineligible or declined
Did not meet eligibility criteria 
Declined
Limited time to consider 
Too overwhelmed by diagnosis



































Received treatment Received treatment
191 191
Included in final analysis 12 months Included in final analysis 12 months
139 135
52 56
Fig 1 | Flowchart of participants. No data were collected for 10 participants: eight randomised in error with bilateral or 
breast reconstruction surgery and two immediate withdrawals due to change of mind
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Characteristics Usual care Exercise Total
Randomised to treatment (n=191) (n=191) (n=382)
Mean (SD) age, years 57.8 (12.0) 58.4 (12.2) 58.1 (12.1)
Mean (SD) body mass index; (missing) 30.6 (7.2); (5) 29.9 (6.9); (6) 30.2 (7.0); (11)
Body mass index:
 <25 44 (23) 50 (26) 94 (25)
 25-<30 51 (27) 53 (28) 104 (27)
 ≥30 91 (48) 82 (43) 173 (45)
 Missing 5 (3) 6 (3) 11 (3)
Axillary surgery:
 Axillary node clearance 162 (85) 165 (86) 327 (86)
 Sentinel lymph node biopsy 26 (14) 26 (14) 52 (14)
 None 2 (1) 0 2 (<1)
 Missing 1 (<1) 0 1 (<1)
Radiotherapy:
 Yes 166 (87) 151 (79) 317 (83)
 No 14 (7) 26 (14) 40 (10)
 Missing 11 (6) 14 (7) 25 (7)
Site of radiotherapy†:
 Breast 114 (60) 94 (49) 208 (54)
 Chest wall 50 (26) 57 (30) 107 (28)
 Axilla/supraclavicular area 62 (32) 51 (27) 113 (30)
Radiotherapy boost given 60 (31) 44 (23) 104 (27)
Chemotherapy given 118 (62) 108 (57) 226 (59)
Axillary node clearance and axillary/supraclavicular radiotherapy 65 (34) 53 (28) 118 (31)
Baseline characteristics‡ (n=175) (n=175) (n=350)
Marital status:
 Single 18 (10) 15 (9) 33 (9)
 Married/cohabiting 127 (73) 124 (71) 251 (72)
 Divorced/separated/widowed 30 (17) 34 (19) 64 (18)
 Missing 0 2 (1) 2 (<1)
Education:
 School only 54 (31) 58 (33) 112 (32)
 Work qualification 36 (21) 35 (20) 71 (20)
 College or university 84 (48) 80 (46) 164 (47)
 Missing 1 (<1) 2 (1) 3 (1)
Employment status:
 Full or part time employed 65 (37) 70 (40) 135 (39)
 Self-employed 6 (3) 10 (6) 16 (5)
 Retired 67 (38) 65 (37) 132 (38)
 Housewife, mother/carer 16 (9) 6 (3) 22 (6)
 Illness/disability/other 16 (9) 23 (13) 39 (11)
 Missing 5 (3) 1 (<1) 6 (2)
Ethnicity:
 White 159 (91) 162 (93) 321 (92)
 Asian 12 (7) 5 (3) 17 (5)
 Afro-Caribbean 1 (<1) 2 (1) 3 (1)
 Mixed 0 (0) 2 (1) 2 (<1)
 Other 2 (1) 3 (2) 5 (1)
 Missing 1 (<1) 1 (<1) 2 (<1)
Comorbidities:
 None 47 (27) 47 (27) 94 (27)
 1-2 86 (49) 90 (51) 176 (50)
 ≥3 42 (24) 38 (22) 80 (23)
Any shoulder problem:
 Yes 29 (17) 45 (26) 74 (21)
 No 120 (69) 105 (60) 225 (64)
 Missing 26 (15) 25 (14) 51 (15)
Upper limb function:
 Mean (SD) DASH; (missing) 18.2 (19.8); (4) 19.5 (21.2); (8) 18.8 (20.5); (12)
 Median (IQR) DASH 11.7 (1.7-30.0) 12.5 (2.5-30.8) 12.3 (1.7-30.2)
Neuropathic pain, DN4:
 No pain 95 (54) 89 (51) 184 (53)
 ≤3 (non-neuropathic pain) 57 (33) 63 (36) 120 (34)
 >3 (neuropathic pain) 17 (10) 16 (9) 33 (9)
 Missing 6 (3) 7 (4) 13 (4)
Mean (SD) pain intensity, NRS; (missing) 1.9 (2.5); (6) 1.9 (2.4); (13) 1.9 (2.4); (13)
Mean (SD) FACT-B+4; (missing) 2.7 (4.0); (0) 3.1 (4.2); (1) 2.9 (4.1); (1)
Table 1 | Participants’ treatment* and baseline characteristics. Values are numbers (percentages) unless stated otherwise
(Continued)
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clinically significant difference in mean DASH scores 
favouring the exercise intervention (unadjusted mean 
difference in DASH 7.34 (95% confidence interval 
2.44 to 12.23; P<0.01); adjusted mean difference in 
DASH 7.81 (3.17 to 12.44; P=0.001) (table 2; fig 2). 
For the complier average causal effect analysis, in 
143/191 (75%) participants who fully adhered to the 
intervention, we observed an increase in the between 
group difference in favour of the PROSPER exercise 
programme (adjusted mean difference in DASH 8.74 
(3.77 to 13.71; P<0.001). We observed no differences 
in effect estimates after multiple imputation for data 
missingness.
We observed improvements at 12 months for all 
DASH subscales of activity limitations, participation 
restrictions, and impairment, favouring exercise 
compared with usual care (supplementary table S1). 
Postoperative pain intensity scores were lower at 
12 months in participants randomised to exercise 
compared with usual care (adjusted mean difference in 
numerical rating scale −0.68, −1.23 to −0.12; P=0.02) 
(table 3). Acute postoperative pain scores at rest and 
on movement were lower in those randomised to 
exercise compared with usual care, but we observed 
no differences in mean pain intensity at six months 
(table 3). We observed fewer arm disability symptoms 
at both six months and 12 months, favouring exercise 
compared with usual care (adjusted mean difference in 
FACT-B+4 −2.02, −3.11 to −0.93; P=0.001) (table 3).
We observed no differences in the rate of neuropathic 
pain, wound related complications (supplementary 
table S2), surgical site infection, lymphoedema, or 
other complications between treatment groups at any 
time point. No serious adverse events were reported. 
Physical health related quality of life scores were 
higher after exercise compared with usual care at 
both six months (adjusted mean difference in SF-12 
physical component summary score 2.73, 0.24 to 
5.21; P=0.03) and 12 months (4.39, 1.74 to 7.04; 
P<0.001) (table 4). We found no differences in mental 
health scores by treatment group over time. Women 
randomised to exercise were more confident in their 
ability to return to usual activities and regular physical 
activity compared with usual care participants, across 
Characteristics Usual care Exercise Total
Lymphoedema, LBCQ:
 Arm feels heavy 38 (22) 43 (25) 81 (23)
 Arm looks swollen 27 (15) 25 (14) 52 (15)
 Arm heavy and swollen 20 (11) 17 (10) 37 (11)
 Arm neither heavy not swollen 152 (87) 148 (85) 300 (86)
 Missing 3 (2) 10 (6) 13 (4)
Health related quality of life:
 Mean (SD) EQ-5D-5L; (missing) 0.67 (0.22); (18) 0.68 (0.20); (16) 0.67 (0.2); (34)
 Mean (SD) SF-12 PCS; (missing) 47.6 (11.6); (8) 46.8 (11.6); (7) 47.2 (11.6); (15)
 Mean (SD) SF-12 MCS; (missing) 44.7 (11.7); (8) 46.8 (10.6); (7) 45.8 (11.2); (15)
Outside walking, days per week:
 Never or seldom (1-2) 38 (22) 46 (26) 84 (24)
 Sometimes (3-4) 51 (29) 54 (31) 105 (30)
 Often (5-7) 85 (49) 75 (43) 160 (46)
 Missing 1 (<1) 0 1 (<1)
Strenuous sport/recreation, days per week:
 Never 134 (77) 132 (75) 266 (76)
 Seldom (1-2) 26 (15) 25 (14) 51 (15)
 Sometimes/often (≥3) 13 (7) 15 (9) 28 (8)
 Missing 2 (1) 3 (2) 5 (1)
Mean (SD) confidence scores; (missing):
 Return to usual activities 7.5 (2.5); (2) 8.1 (2.3); (0) 7.8 (2.4); (2)
 Return to physical activity 7.5 (2.3); (2) 8.0 (2.3); (0) 7.7 (2.3); (2)
DASH=Disability of Arm, Shoulder and Hand; DN4=Dolour Neuropathique-4; FACT-B+4=Functional Assessment of Cancer Therapy-Breast+4 arm scale; 
IQR=interquartile range; LBCQ=Lymphoedema and Breast Cancer Questionnaire; MCS=mental component summary score; NRS=numerical rating scale; 
PCS=physical component summary score.
*Treatment variables are most invasive surgery/adjuvant therapy by 12 month follow-up.
†Radiotherapy administered to >1 site; hence multiple response options possible.
‡350/382 (92%) completed baseline questionnaires pre-randomisation. 
Table 1 | Continued
Table 2 | Disability of Arm, Shoulder, Hand (DASH) scores by treatment group
Time point, analysis
Usual care) Exercise Between group difference (95% CI)*
No Mean (SD) No Mean (SD) Unadjusted P value Adjusted P value
6 months, ITT 125 20.8 (20.1) 134 18.0 (17.1) 2.76 (−1.79 to 7.31) 0.23 4.60 (0.30 to 8.90) 0.04
12 months, ITT (primary outcome) 138 23.7 (22.9) 132 16.3 (17.6) 7.34 (2.44 to 12.23) <0.01 7.81 (3.17 to 12.44) 0.001
12 months, CACE - - 8.35 (2.85 to 13.84) 0.003 8.74 (3.77 to 13.71) <0.001
Baseline to 6 months 118 −5.3 (19.4) 121 0.7 (17.8) 5.96 (1.23 to 10.70) 0.01 4.60 (0.31. 8.90) 0.04
Baseline to 12 months 130 −5.3 (19.7) 117 2.6 (19.7) 7.98 (3.03 to 12.92) <0.01 7.81 (3.17 to 12.44) 0.001
Scores adjusted for age, baseline DASH, breast surgery, axillary surgery, radiotherapy, and chemotherapy. Mean differences in upper limb function favour exercise intervention.
CACE=complier average causal effect; ITT=intention to treat.
*Absolute mean difference between treatment groups.
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all time points, although we observed no differences in 
self-reported activity of walking or strenuous activity 
between treatment groups (supplementary tables S3 
and S4).
The exercise programme cost, on average, an 
additional £129 (€152; $178) per participant. When 
we considered all healthcare and personal social 
services costs, the incremental average cost was 
–£387 (95% confidence interval –£2491 to £1718) 
for the exercise group compared with the usual care 
group, representing a cost saving. When we controlled 
for baseline utility values, the exercise programme 
accrued an average 0.029 (95% confidence interval 
0.001 to 0.056) more QALYs than usual care. This 
was a statistically significant increase (P=0.04). At 
the cost effectiveness threshold values of £20 000 and 
£30 000 per QALY specified by NICE, the probability 
was 78% and 84%, respectively, that exercise was 
the more cost effective of the two arms (fig 3). The 
probability of cost effectiveness at a willingness to 
pay threshold of £20 000 per QALY increased to 97% 
when we excluded the high cost cancer treatment 
(chemotherapy, radiotherapy), which had driven much 
of the uncertainty from the primary analysis. These 
findings remained robust to pre-specified sensitivity 
analyses (supplementary materials).
Discussion
The structured PROSPER exercise programme 
improved upper limb function, postoperative pain, 
arm symptoms, and physical quality of life at 12 
months, compared with usual care alone, in women 
at high risk of upper limb disability after breast 
cancer treatment. We found that our physiotherapy 
led exercise programme, introduced within seven 
to 10 days of breast cancer surgery, did not increase 
wound related complications, neuropathic pain, or 
lymphoedema symptoms at one year. Participants 
exceeded predefined clinically meaningful changes 
for upper limb function, and we observed lower rates 
of chronic postoperative pain and improved health 
related quality of life related to physical functioning 
after exercise than after usual care.
We included women undergoing contemporaneous 
cancer treatment. Axillary clearance procedures 
remain largely unchanged over recent decades, 
whereby tissues, including lymph nodes, bounded 
by the axillary vein, latissimus dorsi, chest wall, 
and pectoralis muscles, are removed. In addition 
to disturbance of the lymphatic system, putative 
mechanisms for postoperative morbidity include 
damage to the intercostobrachial nerve, increasing 
the risk of chronic neuropathic pain.29 Estimates for 





















Fig 2 | Mean (95% confidence interval) Disability of the Arm, Shoulder and Hand (DASH) 
scores by treatment group over time. DASH scores for intention to treat analysis, 
adjusted for age, baseline DASH, breast surgery, axillary surgery, radiotherapy, and 
chemotherapy. Higher scores indicate more disability
Table 3 | Secondary outcomes of pain, arm symptoms, and lymphoedema by treatment group. Values are numbers 
(percentages) unless stated otherwise
Outcome Usual care Exercise Estimate P value
Mean (SD) pain intensity, NRS*: Adjusted mean difference (95% CI)
 Pain at rest, 6 weeks 2.2 (2.5); (n=150) 1.6 (1.9); (n=153) −0.58 (−1.09 to −0.07) 0.03
 Pain on movement, 6 weeks 2.6 (2.6); (n=150) 2.1 (2.1); (n=153) 0.55 (−1.10 to −0.01) 0.04
 Pain, 6 months 2.2 (2.3); (n=153) 2.0 (2.1); (n=148) −0.17 (−0.70 to 0.35) 0.52
 Pain, 12 months 2.6 (2.4); (n=139) 1.9 (2.0); (n=135) −0.68 (−1.23 to −0.12) 0.02
Adjusted odds ratio (95% CI)
 Moderate to severe, 6 weeks 46/150 (31) 28/153 (18) 1.90 (1.02 to 3.52) 0.04
 Moderate to severe, 6 months 30/133 (23) 25/145 (17) 1.42 (0.72 to 2.84) 0.31
 Moderate to severe, 12 months 43/139 (31) 22/135 (16) 2.41 (1.24 to 4.70) 0.01
Neuropathic pain, DN4 positive: Adjusted odds ratio (95% CI)
 6 weeks 21/150 (14) 24/153 (16) 0.73 (0.22 to 2.45) 0.61
 6 months 29/133 (22) 26/145 (18) 1.64 (0.63 to 4.23) 0.31
 12 months 32/139 (23) 22/135 (16) 1.29 (0.45 to 3.69) 0.64
Mean (SD) arm symptoms, FACT-B+4: Adjusted mean difference (95% CI)
 6 weeks 4.5 (4.4) 4.1 (3.8) −0.48 (−1.40 to 0.43) 0.30
 6 months 4.7 (4.4) 3.4 (3.4) −1.11 (−2.01 to −0.21) 0.02
 12 months 5.4 (5.2) 3.4 (4.0) −2.02 (−3.11 to −0.93) <0.001
Lymphoedema, LBCQ: Adjusted odds ratio (95% CI)
 6 weeks 20/150 (13) 22/153 (14) 1.07 (0.52 to 2.24) 0.85
 6 months 32/133 (24) 29/145 (20) 0.82 (0.43 to 1.56) 0.55
 12 months 36/139 (26) 33/135 (24) 1.17 (0.62 to 2.23) 0.62
DN4=Douleur Neuropathique-4 (positive neuropathic pain=score >3); FACT-B+4=Functional Assessment of Cancer Therapy-Breast+4 arm symptom scale; 
LBCQ=Lymphoedema and Breast Cancer Questionnaire (positive symptoms=arm both heavy and swollen).
*Numerical rating scale: acute and chronic postoperative pain. Moderate to severe pain=4-10.
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studies consistently report higher rates of shoulder 
impairment and chronic pain after axillary node 
clearance than after sentinel lymph node biopsy.2 30 
Radiation is independently correlated with upper limb 
morbidity: a network meta-analysis including 21 trials 
found that patients treated with axillary node clearance 
and radiotherapy targeting the supraclavicular area 
and chest wall were at increased risk of developing 
lymphoedema, with the greatest risk among those 
receiving regional node irradiation.31
Comparison with other studies
Systematic reviews highlight the paucity of high 
quality evidence on the timing, safety, and optimal 
content of postoperative exercise after non-
reconstructive breast cancer surgery.46 A meta-analysis 
reported low quality evidence for the effectiveness 
of early rehabilitation on upper limb function up to 
six months postoperatively (three trials; total 526 
participants, of whom 154 allocated to exercise).7 
Low level evidence also exists for the safety of muscle 
strengthening after axillary node clearance (two 
trials; 422 participants; follow-up six months). We 
aimed to fill this gap by investigating the efficacy 
of early structured rehabilitation on functional and 
health related outcomes over one year. We measured 
upper limb function with the DASH, which has been 
shown to detect and differentiate changes in disability 
over time after surgery and for other upper extremity 
musculoskeletal disorders. The accepted minimally 
important clinical difference for people with painful 
disability is 10, but we accepted a smaller difference 
of seven as the study hypothesis was the prevention of 
post-treatment upper limb impairment. Most women in 
our study did not have severe upper limb dysfunction 
preoperatively, reflected in our sample’s mean baseline 
DASH scores (mean DASH 19), compared with studies 
of other conditions such as shoulder arthroplasty 
(mean DASH 64) or elbow arthroplasty (mean DASH 
59).24 An improvement in DASH of five to 10 points 
indicates moderate improvement.25 Our intention 
to treat analyses suggests an observed effect size of 
0.4, which may be considered modest but clinically 
worthwhile, given the pragmatic design and extended 
follow-up.32 Furthermore, our complier average causal 
effect analyses showed a 9 point change in DASH at 12 
months among participants who were fully adherent to 
the exercise programme. Participants’ adherence was 
high, with 75% (143/191) attending the minimum 
three physiotherapy contacts. Strength exercises, 
using resistance bands, introduced at one month 
postoperatively were not associated with increased 
risk of lymphoedema, although we are aware that a 
risk of late onset lymphoedema, developing beyond 
12 months, remains. We observed early benefits for 
some but not all secondary outcomes, with lower pain 
scores at six weeks and fewer arm symptoms at six 
weeks and six months in participants randomised to 
exercise (table 3). Fewer women allocated to exercise 
reported clinically meaningful moderate to severe 
intensity pain at one year (exercise 16% versus usual 
care 31%; table 3). We found no differences in rates 
of chronic neuropathic pain, concluding that early, 
progressive mobilisation was safe over the short and 
longer term. However, our exercise programme did 
not affect physical activity at one year: daily walking 
and strenuous activity levels were similar across the 
groups, with only one third of all women participating 
in strenuous sport on a weekly basis by one year 
(supplementary table S4). These activity levels are 
below international recommendations for physical 
activity.33
A systematic review found contrasting evidence for 
the cost effectiveness of exercise rehabilitation after 
breast cancer surgery, with only one Australian trial 
reporting health consequences expressed in QALYs 
over a 12 month horizon (sample size 194; mean QALY 
difference 0.009).8 Ours is the first UK cost effectiveness 
study, and we found that implementation of exercise 
was low cost (mean £129 per participant) and was 
associated with lower overall healthcare and personal 
social service costs and improved health related quality 
of life compared with usual care. Given that EQ-5D-5L 
scores were diverging in favour of exercise at 12 months, 
Table 4 | Health related quality of life (SF-12) scores by treatment group
Usual care Exercise Unadjusted estimate (95% CI) P value Adjusted estimate (95% CI) P value
6 months (n=133) (n=145)
Mean (SD) PCS; (missing) 43.2 (11.2); (5) 45.9 (9.5); (9) 2.73 (0.21, 5.25) 0.03 2.73 (0.24 to 5.21) 0.03
Mean (SD) MCS; (missing) 45.9 (11.1); (5) 48.0 (9.8); (9) 2.11 (−0.42, 4.64) 0.10 2.12 (−0.37 to 4.61) 0.09
12 months (n=139) (n=135)
Mean (SD) PCS; (missing) 43.8 (11.5); (7) 48.1 (10.0); (10) 4.30 (1.63, 6.97) 0.002 4.39 (1.74 to 7.04) <0.001
Mean (SD) MCS; (missing) 46.6 (11.2); (7) 48.7 (10.0); (10) 2.10 (−0.51, 4.71) 0.11 1.99 (−0.58 to 4.57) 0.13
Adjusted for age, baseline SF-12 score, breast surgery, axillary surgery, radiotherapy, and chemotherapy.
MCS=mental component summary score; PCS=physical component summary score.
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Fig 3 | Cost effectiveness acceptability curve. Probability of cost effectiveness of 
exercise programme at alternative willingness to pay thresholds for an additional 
quality adjusted life year (QALY) held by decision makers. Increased values indicate 
higher probabilities of cost effectiveness for intervention programme
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these are conservative estimates, and concluding that 
this would increase if the time horizon was extended 
is reasonable, assuming that the exercise programme 
follows the trajectory of continuing to accrue more 
QALYs than usual care. Much of the uncertainty 
surrounding cost effectiveness estimates was driven by 
the large and variable costs of other cancer treatments, 
including adjuvant chemotherapy, that might not be 
directly related to upper limb dysfunction. On removal 
of these costs, the probability that the intervention was 
cost effective at the £20 000 per QALY threshold was 
97%.
Strengths and limitations of study
The strengths of this study include the substantially 
larger sample size compared with previous trials, long 
follow-up period, high adherence to the intervention, 
multicentre involvement, and robust allocation 
concealment. The standardised exercise protocol was 
delivered by NHS physiotherapists from 17 different 
cancer units serving geographically diverse localities 
across England. The programme was co-developed 
with patients and clinical experts, resulting in a 
theoretically informed, fully manualised exercise 
intervention, incorporating behavioural change 
strategies and principles of exercise prescription 
based on the American College of Sports Medicine 
and American Cancer Society guidelines for cancer 
survivors.10 14 Quality was assessed across all centres, 
so we are confident of treatment fidelity and avoidance 
of drift from the protocol by therapists.
Limitations of PROSPER include the lack of objective 
measurement of the secondary outcome lymphoedema 
by water displacement, arm circumference, or 
instrumental measurements, although this was not 
the primary purpose of our intervention. We used 
the validated patient reported Lymphoedema Breast 
Cancer Questionnaire,21 which has been shown to 
correlate with early onset of lymphoedema and is also 
being used as a primary outcome in other recently 
funded lymphoedema trials.34 Participants and 
physiotherapists were not masked to treatment, but 
this is an unavoidable limitation of therapy trials. We 
anticipated 25% loss to follow-up but observed slightly 
higher follow-up rates than predicted (78%); our 
participants were well matched with regards to cancer 
treatment, and losses were equally distributed by 
treatment allocation. Most drop-out occurred over the 
first six months, during active cancer treatments, with 
minimal loss thereafter. Imputation methods to assess 
the effect of data missingness did not alter the strength 
or direction of estimates of effect. Despite attrition, our 
trial was adequately powered for the primary outcomes, 
as the required sample size was 242 participants. 
Finally, our economic sensitivity analysis that used 
hospital episode statistics data was performed on a 
subset of participants and therefore may not be fully 
representative of the whole sample. However, these 
data capture only hospital admissions and therefore 
will have missed those costs (savings) most likely to be 
attributable to the exercise intervention.
Implications for policy and practice
The PROSPER structured exercise programme 
introduced at one week postoperatively was safe 
to deliver, clinically impactful, and cost effective, 
providing the best quality evidence to date in support 
of prescription of early exercise for women at high risk 
of shoulder problems and upper limb morbidity after 
non-reconstructive breast cancer treatment. Future 
research directions could evaluate application of our 
preoperative screening criteria for the identification 
of women at higher risk of developing post-treatment 
limb related disability who could benefit from this cost 
effective exercise programme.
Conclusions
We found robust evidence that early, structured, 
progressive exercise is safe and clinically effective for 
women at high risk of developing shoulder and upper 
limb problems after non-reconstructive breast surgery. 
The PROSPER exercise programme improved upper 
limb function at one year after breast cancer surgery 
and was cost effective compared with usual NHS care. 
Our manualised exercise intervention is suitable for 
wider implementation in clinical practice.
We thank all study participants, research staff, and surgical and 
physiotherapy teams for their support in the successful delivery of the 
PROSPER trial.
UK PROSPER trial collaborators: C Lait, C Hegarty, M van Laar 
(patient representative), C Harkin (patient representative, deceased), 
L Chowdhury, H Richmond, L Betteley, C Srikesavan, M Newman, J 
Moser. Principal investigators: A Tomlins, K McEvoy, PG Roy, R Soulsby, 
F Hoar, JS McNicholas, I Azmy, S Mitchell, C Osborne, J Donnelly, E 
Babu, N van de Ploeg, T Sircar, K Makam, E McLoughlin, M Noblet, 
S Soumian, A Thorne, L Wagstaff. Physiotherapists (intervention 
delivery): C Hegarty, L Fort (deceased), C Rushton, M Evans, A 
Simpson, L Ridgeway, D Pilgrim, L Graves, K Jones, J Holt, N Ekers, A 
McMullen, C Lindsay, S Wright, R Bower, S Horne, S Rook, N Redfern, A 
Allen, S Greenwood, E McLoughlin, A Stephenson, R Conway, C Edley, 
J Pitts, N Layte, H Thomas, C Johnson, A Heath, L Beadle, R Scarisbrick, 
D DeBeer, D Dungey, Y Stokes, S Calloway, H Brown, N Clarke. Quality 
assurance: C Daffern. Programming: A Willis, H Adjei, C Muthiah.
Trial Steering Committee: A Francis (deceased), S Duffy, A Kirby, K 
Robb, M van Laar (patient representative).
Data Monitoring and Ethics Committee: M Reed, R Gabe, M 
Maddocks.
Trial co-sponsors: University of Warwick and University Hospitals 
Coventry and Warwickshire NHS Trust.
Contributors: JB, EW, SL, RL, AMT, and SP were responsible for 
securing funding, design of the trial and intervention, and oversight 
of study management. RL oversaw statistical analysis undertaken by 
PM and AH. AC and SP were responsible for health economic analysis. 
BM and JB oversaw delivery of the intervention. SR coordinated 
patient representation and qualitative research. EP coordinated 
trial management. All authors were responsible for interpretation of 
data and for approving the draft manuscript. JB is the guarantor. The 
corresponding author attests that all listed authors meet authorship 
criteria and that no others meeting the criteria have been omitted.
Funding: UK National Institute for Health Research (NIHR) Health 
Technology Assessment Programme project 13/84/10. JB 
acknowledges support from NIHR Research Capability Funding via 
University Hospitals Coventry and Warwickshire NHS Trust. EW is 
supported by the National Institute for Health Research Applied 
Research Collaboration Oxford and Thames Valley at Oxford 
Health NHS Foundation Trust. SP receives support as a NIHR senior 
investigator (NF-SI-0616-10103) and from the NIHR Applied 
Research Collaboration Oxford and Thames Valley. The funders had 
no role in considering the study design or in the collection, analysis, 
interpretation of data, writing of the report, or decision to submit the 
article for publication. The corresponding author had full access to 
study data and had final responsibility to submit for publication.
copyright.
 on 11 N
ovem













J: first published as 10.1136/bm







the bmj | BMJ 2021;375:e066542 | doi: 10.1136/bmj-2021-066542 11
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/disclosure-of-interest/ and declare: 
support from the UK National Institute for Health Research (NIHR) 
Technology Assessment Programme; JB received grants from the UK 
NIHR during the conduct of this study and is a member of the NIHR 
Research for Patient Benefit board; SL reports membership of the UK 
NIHR Health Technology Assessment (HTA) Additional Capacity Funding 
Board, HTA End of Life Care and Add-on Studies Board, HTA Prioritisation 
Group Board, and HTA Trauma Board; no other relationships or activities 
that could appear to have influenced the submitted work.
Ethical approval: The West Midlands Solihull Research Ethics 
Committee approved the study on 20 July 2015 (reference 15/
WM/0224). Each cancer centre was granted site specific approval 
from respective NHS trust research and development departments 
before the start of the trial.
Data sharing: All data requests should be submitted to the 
corresponding author for consideration. Access to anonymised data may 
be granted following review. Data will be shared, with investigator support, 
after approval of a proposal, with a signed data access agreement. The 
study protocol and intervention materials are available online.
The lead author affirms that the manuscript is an honest, accurate, 
and transparent account of the study being reported; that no 
important aspects of the study have been omitted; and that any 
discrepancies from the study as planned (and, if relevant, registered) 
have been explained.
Dissemination to participants and related patient and public 
communities: We had invited trial participants to a dissemination 
event in March 2020, but this was cancelled owing to covid-19. 
We will publish a plain language summary of study results on the 
University of Warwick Clinical Trials Unit website for trial participants 
and distribute it to cancer units and physiotherapy departments 
involved in the research.
Provenance and peer review: Not commissioned; externally peer 
reviewed.
This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which 
permits others to distribute, remix, adapt and build upon this work, 
for commercial use, provided the original work is properly cited. See: 
http://creativecommons.org/licenses/by/4.0/.
1  Lee TS, Kilbreath SL, Refshauge KM, Herbert RD, Beith JM. Prognosis of 
the upper limb following surgery and radiation for breast cancer. Breast 
Cancer Res Treat 2008;110:19-37. doi:10.1007/s10549-007-9710-9 
2  Mejdahl MK, Andersen KG, Gärtner R, Kroman N, Kehlet H. Persistent 
pain and sensory disturbances after treatment for breast cancer: 
six year nationwide follow-up study. BMJ 2013;346:f1865. 
doi:10.1136/bmj.f1865 
3  National Institute for Health and Care Excellence. Early and locally 
advanced breast cancer: diagnosis and management. 2018. https://
www.nice.org.uk/guidance/ng101.
4  McNeely ML, Campbell K, Ospina M, et al. Exercise interventions for 
upper-limb dysfunction due to breast cancer treatment. Cochrane 
Database Syst Rev 2010;(6):CD005211. doi:10.1002/14651858.
CD005211.pub2 
5  DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm 
lymphoedema after breast cancer: a systematic review and meta-
analysis. Lancet Oncol 2013;14:500-15. doi:10.1016/S1470-
2045(13)70076-7 
6  De Groef A, Van Kampen M, Dieltjens E, et al. Effectiveness of 
postoperative physical therapy for upper-limb impairments after 
breast cancer treatment: a systematic review. Arch Phys Med 
Rehabil 2015;96:1140-53. doi:10.1016/j.apmr.2015.01.006 
7  Ribeiro IL, Moreira RFC, Ferrari AV, Alburquerque-Sendín F, Camargo 
PR, Salvini TF. Effectiveness of early rehabilitation on range of 
motion, muscle strength and arm function after breast cancer 
surgery: a systematic review of randomized controlled trials. Clin 
Rehabil 2019;33:1876-86. doi:10.1177/0269215519873026 
8  Khan KA, Mazuquin B, Canaway A, Petrou S, Bruce J. Systematic 
review of economic evaluations of exercise and physiotherapy 
for patients treated for breast cancer. Breast Cancer Res 
Treat 2019;176:37-52. doi:10.1007/s10549-019-05235-7 
9  Bruce J, Williamson E, Lait C, et al, PROSPER Study Group. 
Randomised controlled trial of exercise to prevent shoulder problems 
in women undergoing breast cancer treatment: study protocol 
for the prevention of shoulder problems trial (UK PROSPER). BMJ 
Open 2018;8:e019078. doi:10.1136/bmjopen-2017-019078 
10  Richmond H, Lait C, Srikesavan C, et al, PROSPER Study Group. 
Development of an exercise intervention for the prevention of 
musculoskeletal shoulder problems after breast cancer treatment: 
the prevention of shoulder problems trial (UK PROSPER). BMC Health 
Serv Res 2018;18:463. doi:10.1186/s12913-018-3280-x 
11  Rees S, Mazuquin B, Richmond H, Williamson E, Bruce J, UK PROSPER 
Study Group. Role of physiotherapy in supporting recovery from 
breast cancer treatment: a qualitative study embedded within the 
UK PROSPER trial. BMJ Open 2021;11:e040116. doi:10.1136/
bmjopen-2020-040116 
12  Breast Cancer Care. Exercises after breast cancer surgery. Breast 
Cancer Care, 2013.
13  Breast Cancer Care. Your operation and recovery. Breast Cancer Care, 
2013.
14  Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and 
physical activity guidelines for cancer survivors. CA Cancer J 
Clin 2012;62:243-74. doi:10.3322/caac.21142 
15  Hudak PL, Amadio PC, Bombardier C, The Upper Extremity 
Collaborative Group (UECG). Development of an upper extremity 
outcome measure: the DASH (disabilities of the arm, shoulder and 
hand) [corrected]. Am J Ind Med 1996;29:602-8. doi:10.1002/
(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L 
16  Harrington S, Michener LA, Kendig T, Miale S, George SZ. Patient-
reported upper extremity outcome measures used in breast cancer 
survivors: a systematic review. Arch Phys Med Rehabil 2014;95:153-
62. doi:10.1016/j.apmr.2013.07.022 
17  Miale S, Harrington S, Kendig T. Oncology Section Task Force on Breast 
Cancer Outcomes: clinical measures of upper extremity function. Rehabil 
Oncol 2013;30:8. doi:10.1097/01893697-201331010-00006.
18  Dixon D, Johnston M, McQueen M, Court-Brown C. The Disabilities 
of the Arm, Shoulder and Hand Questionnaire (DASH) can measure 
the impairment, activity limitations and participation restriction 
constructs from the International Classification of Functioning, 
Disability and Health (ICF). BMC Musculoskelet Disord 2008;9:114. 
doi:10.1186/1471-2474-9-114 
19  Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence 
of chronic pain with neuropathic characteristics in the general 
population. Pain 2008;136:380-7. doi:10.1016/j.pain.2007.08.013 
20  Coster S, Poole K, Fallowfield LJ. The validation of a quality of 
life scale to assess the impact of arm morbidity in breast cancer 
patients post-operatively. Breast Cancer Res Treat 2001;68:273-82. 
doi:10.1023/A:1012278023233 
21  Armer JM, Radina ME, Porock D, Culbertson SD. Predicting breast 
cancer-related lymphedema using self-reported symptoms. Nurs 
Res 2003;52:370-9. doi:10.1097/00006199-200311000-00004 
22  QualityMetric. An abridged version of the SF-36v2® Health Survey 
that uses 12 items to measure functional health and well-being from 
the patient’s point of view. 2021. https://www.qualitymetric.com/
health-surveys-old/the-sf-12v2-health-survey/.
23  van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the 
EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value 
Health 2012;15:708-15. doi:10.1016/j.jval.2012.02.008 
24  Angst F, John M, Pap G, et al. Comprehensive assessment of clinical 
outcome and quality of life after total elbow arthroplasty. Arthritis 
Rheum 2005;53:73-82. doi:10.1002/art.20911 
25  Sorensen AA, Howard D, Tan WH, Ketchersid J, Calfee RP. Minimal 
clinically important differences of 3 patient-rated outcomes 
instruments. J Hand Surg Am 2013;38:641-9. doi:10.1016/j.
jhsa.2012.12.032 
26  Beurskens CH, van Uden CJ, Strobbe LJ, Oostendorp RA, Wobbes 
T. The efficacy of physiotherapy upon shoulder function following 
axillary dissection in breast cancer, a randomized controlled study. 
BMC Cancer 2007;7:166. doi:10.1186/1471-2407-7-166 
27  Curtis L. Unit Costs of Health and Social Care 2016. University of 
Kent, 2016.
28  National Institute for Health and Care Excellence. Guide to the 
Methods of Technology Appraisal. NICE, 2013.
29  Meretoja TJ, Andersen KG, Bruce J, et al. Clinical Prediction Model and 
Tool for Assessing Risk of Persistent Pain After Breast Cancer Surgery. 
J Clin Oncol 2017;35:1660-7. doi:10.1200/JCO.2016.70.3413 
30  Hidding JT, Beurskens CH, van der Wees PJ, van Laarhoven HW, 
Nijhuis-van der Sanden MW. Treatment related impairments in arm 
and shoulder in patients with breast cancer: a systematic review. 
PLoS One 2014;9:e96748. doi:10.1371/journal.pone.0096748 
31  Shaitelman SF, Chiang YJ, Griffin KD, et al. Radiation therapy 
targets and the risk of breast cancer-related lymphedema: a 
systematic review and network meta-analysis. Breast Cancer Res 
Treat 2017;162:201-15. doi:10.1007/s10549-016-4089-0 
32  Rothwell JC, Julious SA, Cooper CL. A study of target effect sizes in 
randomised controlled trials published in the Health Technology 
Assessment journal. Trials 2018;19:544. doi:10.1186/s13063-
018-2886-y 
33  World Health Organization. Global strategy on diet, physical activity 
and health. WHO, 2004.
34  Axillary Management in Breast Cancer Patients With Needle Biopsy 
Proven Nodal Metastases After Neoadjuvant Chemotherapy (ATNEC). 
2021. https://clinicaltrials.gov/ct2/show/NCT04109079.
Web appendix: Supplementary materials
copyright.
 on 11 N
ovem













J: first published as 10.1136/bm
j-2021-066542 on 10 N
ovem
ber 2021. D
ow
nloaded from
 
